{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:40:16Z","timestamp":1770748816678,"version":"3.50.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40257-025-00951-x","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T13:46:40Z","timestamp":1748094400000},"page":"795-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort Study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Jo\u00e3o","sequence":"additional","affiliation":[]},{"given":"Martim","family":"Luz","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[]},{"given":"\u00c2ngela","family":"Roda","sequence":"additional","affiliation":[]},{"given":"Luiz","family":"Leite","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Val\u00e9rio","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Ferreirinha","sequence":"additional","affiliation":[]},{"given":"Barbara","family":"Leal","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Paiva Lopes","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Pimenta","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"12","key":"951_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40265-020-01357-1","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair HA. Risankizumab: a review in moderate to severe plaque psoriasis. Drugs. 2020;80(12):1235\u201345.","journal-title":"Drugs"},{"issue":"3","key":"951_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/picr.picr_62_21","volume":"12","author":"D Chodankar","year":"2021","unstructured":"Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021;12(3):171\u20134.","journal-title":"Perspect Clin Res"},{"issue":"1","key":"951_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/jdv.19956","volume":"39","author":"N Rompoti","year":"2025","unstructured":"Rompoti N, Stefanaki I, Panagakiset P, al. Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2025;39(1):e1-4.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"951_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ad.2024.02.030","volume":"116","author":"A Martorell-Calatayud","year":"2025","unstructured":"Martorell-Calatayud A, Santos-Alarc\u00f3n S, Sahuquillo-Torralba A,\u00a0et al. Real-world safety and efficacy of risankizumab in psoriatic patients: a multicenter, retrospective, and not-interventional study. Actas Dermosifiliogr. 2025;116(2):125\u201333.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"951_CR5","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/jdv.19464","volume":"38","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2024;38(1):e113\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"951_CR6","doi-asserted-by":"publisher","first-page":"adv00354","DOI":"10.2340\/00015555-3711","volume":"101","author":"CP Hernandez-Fernandez","year":"2021","unstructured":"Hernandez-Fernandez CP,\u00a0Carretero G, Rivera R,  et al. Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort. Acta Derm Venereol. 2021;101(1):adv00354.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"951_CR7","first-page":"734","volume":"16","author":"RGB Langley","year":"2017","unstructured":"Langley RGB,\u00a0Reich K, Papavassilis C,  et al. Methods for imputing missing efficacy data in clinical trials of biologic psoriasis therapies: implications for interpretations of trial results. J Drugs Dermatol. 2017;16(8):734\u201341.","journal-title":"J Drugs Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00951-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:02:45Z","timestamp":1757966565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00951-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00951-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB. Tiago Torres is an Editorial Board member of the American Journal of Clinical Dermatology. Professor Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ana Lu\u00edsa Jo\u00e3o has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Janssen, Leo Pharma, Merck, Novartis, and Sanofi. Martim Luz has no conflicts of interest that are directly relevant to the content of this article. Pedro Mendes-Bastos has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Alumis, Amgen, Apogee, Biogen, CS Labs, Eli-Lilly, Evelo Biosciences, Janssen-Cilag, Leo-Pharma, L\u2019Oreal, Novartis, Organon, Pfizer, Pierre Fabre, Regeneron, Sanofi, and Viatris. \u00c2ngela Roda has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Janssen, and Novartis. Luiz Leite, Joana Val\u00e9rio, Ana Ferreirinha, and Barbara Leal have no conflicts of interest that are directly relevant to the content of this article. Maria Jo\u00e3o Paiva Lopes has participated in clinical trials, advisory board, and\/or lectures promoted by AbbVie, Almirall, Boehringer Ingelheim, Janssen, Leo-Pharma, Eli Lilly, Novartis, Pfizer, Sanofi-Genzyme, and Viatris. Rita Pimenta has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Janssen, and LEO Pharma. Paulo Ferreira has received consultancy and\/or speaker\u2019s honoraria from AbbVie, Almirall, Janssen, LEO Pharma, Lilly, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient consent was exempted because of the retrospective nature of the study and the use of de-identified, anonymized, and aggregated data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that supports the findings of this article are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed equally to the conception, design, data analysis, and manuscript preparation. All authors reviewed and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}